Arthritis Care & Research最新文献

{"title":"Reply.","authors":"Lingling Cui, Wenyan Sun, Changgui Li","doi":"10.1002/acr.25592","DOIUrl":"10.1002/acr.25592","url":null,"abstract":"","PeriodicalId":8406,"journal":{"name":"Arthritis Care & Research","volume":" ","pages":""},"PeriodicalIF":3.3,"publicationDate":"2025-06-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144526279","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Risk of hepatotoxicity in use of febuxostat or benzbromarone: comment on the article by Sun et al.","authors":"Shih-Wei Lai, Kuan-Fu Liao","doi":"10.1002/acr.25587","DOIUrl":"10.1002/acr.25587","url":null,"abstract":"","PeriodicalId":8406,"journal":{"name":"Arthritis Care & Research","volume":" ","pages":""},"PeriodicalIF":3.3,"publicationDate":"2025-06-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144526281","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Febuxostat use is associated with a significantly greater risk of mild to moderate perturbation of liver function compared to benzbromarone in patients with gout: comment on the article by Sun et al.","authors":"Gang Wang, Zhichun Liu","doi":"10.1002/acr.25591","DOIUrl":"10.1002/acr.25591","url":null,"abstract":"","PeriodicalId":8406,"journal":{"name":"Arthritis Care & Research","volume":" ","pages":""},"PeriodicalIF":3.3,"publicationDate":"2025-06-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144526278","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Correction to \"Effects of Social Vulnerability and Environmental Burden on Care Fragmentation and Social Needs Among Individuals with Rheumatic Conditions\".","authors":"","doi":"10.1002/acr.25585","DOIUrl":"https://doi.org/10.1002/acr.25585","url":null,"abstract":"","PeriodicalId":8406,"journal":{"name":"Arthritis Care & Research","volume":" ","pages":""},"PeriodicalIF":3.7,"publicationDate":"2025-06-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144493825","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Time Trends and Predictors of Gout Remission Over 6 Years.","authors":"Adwoa Dansoa Tabi-Amponsah, Sarah Stewart, Greg Gamble, Lisa K Stamp, William J Taylor, Nicola Dalbeth","doi":"10.1002/acr.25584","DOIUrl":"10.1002/acr.25584","url":null,"abstract":"<p><strong>Objective: </strong>This study aims to describe the trends in remission rates over 6 years of follow-up among people with gout taking urate-lowering therapy (ULT) and to identify variables that predict remission.</p><p><strong>Methods: </strong>A post hoc analysis was conducted using data from the Cardiovascular Safety of Febuxostat or Allopurinol in Patients with Gout (CARES) trial, which enrolled people with gout and cardiovascular disease randomized to febuxostat or allopurinol. Gout remission over 6 years of follow-up was measured in participants with at least 1 year of follow-up data using the simplified gout remission definition, requiring the fulfillment of three domains: (1) no gout flares during the past year, (2) at least two serum urate measurements <0.36 mmol/L during the past year, and (3) no tophus. Logistic regression was used to identify baseline predictors of remission.</p><p><strong>Results: </strong>Achievement of remission increased from 37.4% of participants (1,593/4,259) at year 1 to 63.1% (322/510) at year 6. Over the 6 years, 59.4% of participants achieved remission at least once. More participants receiving febuxostat achieved remission during the first 2 years, primarily because of a higher number achieving the serum urate remission domain. In multivariable analysis, baseline age, race, greater disease severity, presence of comorbidities, and febuxostat treatment were variables significantly associated with remission.</p><p><strong>Conclusion: </strong>On ULT, fulfillment of remission increases over time and remission can be achieved in most patients. Baseline predictors, including demographics, comorbidities, and disease severity, may be useful to identify people with gout who need more proactive management to achieve remission.</p>","PeriodicalId":8406,"journal":{"name":"Arthritis Care & Research","volume":" ","pages":""},"PeriodicalIF":3.3,"publicationDate":"2025-06-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144315784","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Rheumatoid Arthritis and Risk of Thyroid Cancer: A Nationwide Cohort Study","authors":"Mi Hee Cho,&nbsp;Jinhyung Jung,&nbsp;Tae Hyuk Kim,&nbsp;Kyungdo Han,&nbsp;Dagyeong Lee,&nbsp;Keun Hye Jeon,&nbsp;In Young Cho,&nbsp;Dong Wook Shin","doi":"10.1002/acr.25582","DOIUrl":"10.1002/acr.25582","url":null,"abstract":"<div>\u0000 \u0000 <section>\u0000 \u0000 <h3> Objective</h3>\u0000 \u0000 <p>Despite extensive cancer-related research in patients with rheumatoid arthritis (RA), there remains a paucity of studies on thyroid cancer in patients with RA. We investigated the risk of thyroid cancer in patients with RA using updated definitions to identify patients with RA and incident cases of thyroid cancer with consideration of RA serologic status.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>Using a nationwide database, we identified 40,895 patients with newly diagnosed RA between 2010 and 2017 and matched them by sex and age at a 1:5 ratio to a control population of 204,475 individuals without RA. The association of thyroid cancer and RA with consideration of serostatus was investigated using Cox regression analyses. Stratified analyses by sex and age were conducted using the same Cox modeling.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>During 5.5 years of follow-up, compared to the matched control group, the adjusted hazard ratio (aHR) of thyroid cancer in patients with overall RA was 0.98 (95% confidence interval [CI] 0.85–1.13). Compared to the seronegative patients with RA, seropositive patients with RA did not show a significantly different risk of thyroid cancer (aHR 1.03, 95% CI 0.78–1.36). Stratified analyses by age or sex showed no statistical interaction.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusion</h3>\u0000 \u0000 <p>Patients with newly diagnosed RA did not show a different risk of thyroid cancer compared to a matched control group. The risk of thyroid cancer incidence was not affected by serologic status of RA, sex, or age.</p>\u0000 </section>\u0000 </div>","PeriodicalId":8406,"journal":{"name":"Arthritis Care & Research","volume":"77 11","pages":"1359-1367"},"PeriodicalIF":3.3,"publicationDate":"2025-06-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144282242","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Effect of Nonsteroidal Anti-Inflammatory Drugs on Sacroiliac Joint Inflammation, as Seen on Magnetic Resonance Imaging, in Axial Spondyloarthritis.","authors":"Gareth T Jones, Alexander N Bennett, Raj Sengupta, Pedro M Machado, Helena Marzo-Ortega, Lorna Aucott, Margaret A Hall-Craggs, Timothy J P Bray, Alan Bainbridge, Ruaridh M Gollifer, Gary J Macfarlane","doi":"10.1002/acr.25581","DOIUrl":"10.1002/acr.25581","url":null,"abstract":"<p><strong>Objective: </strong>Imaging evidence of active sacroiliitis is important for diagnosis, classification, and monitoring of axial spondyloarthritis (axSpA). However, there is no consistent guidance on whether patients should temporarily stop nonsteroidal anti-inflammatory drugs (NSAIDs) before magnetic resonance imaging (MRI). The aim of this study was to determine whether NSAIDs lead to an underestimation of active sacroiliitis, as observed using MRI.</p><p><strong>Methods: </strong>Adults with axSpA were recruited from rheumatology clinics and undertook NSAID washout for one to two weeks before a sacroiliac joint MRI scan. Images were read by two independent readers and adjudicated by a third if required. Those who had a positive result for active sacroiliitis, as per internationally recognized criteria, underwent a second scan six weeks after recommencing daily NSAIDs. We determined the proportion of participants who had a negative scanning result while taking NSAIDs after a previous positive result when NSAID-free. Images were also scored using semiquantitative methods comprising lesion size and intensity, and a subset of participants underwent quantitative MRI (qMRI) to provide an objective evaluation of any inflammatory changes.</p><p><strong>Results: </strong>From 34 centers across the United Kingdom, 311 participants (median age 42 years; 62% male) were recruited; 286 (92%) completed the NSAID washout and underwent the first MRI scan. From 146 participants with active sacroiliitis, follow-up scans (while taking NSAIDs) were obtained from 124 (85%), at which point 25 participants had a negative result (20.2%; 95% confidence interval 13.5%-28.3%). Semiquantitative and qMRI methods supported these findings.</p><p><strong>Conclusion: </strong>One-fifth of patients showed full resolution of active sacroiliitis lesions when NSAIDs were present. In clinical practice, if patients with axSpA are willing to attempt a one- to two-week NSAID washout before MRI, this should be considered.</p>","PeriodicalId":8406,"journal":{"name":"Arthritis Care & Research","volume":" ","pages":""},"PeriodicalIF":3.3,"publicationDate":"2025-06-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144282240","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Predicting the Impact of Air Quality Index on Rheumatoid Arthritis Disease Activity","authors":"Ahmad Alsaber,&nbsp;Adeeba Al-Herz,&nbsp;Maryam Al-Mazedi,&nbsp;Iyad Abu Doush,&nbsp;Afsah Abdullah,&nbsp;Dhary Alkandary,&nbsp;Ahmad T. Al-Sultan,&nbsp;Parul Setiya,&nbsp;Jiazhu Pan","doi":"10.1002/acr.25583","DOIUrl":"10.1002/acr.25583","url":null,"abstract":"<div>\u0000 \u0000 <section>\u0000 \u0000 <h3> Objective</h3>\u0000 \u0000 <p>This study explored the relationship between air pollution and rheumatoid arthritis (RA), focusing on how specific air quality components affect RA disease activity as measured by the Disease Activity Score in 28 joints (DAS28).</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>The research involved data that were obtained from six air-monitoring stations across Kuwait, and information on patients with RA was obtained from the Kuwait Registry for Rheumatic Diseases. This study analyzed the impact of pollutants such as sulfur dioxide, nitrogen dioxide (NO₂), ozone (O₃), particulate matter with a diameter of 10 micrometers or less, nitrogen oxide, and carbon monoxide on the DAS28.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>The results highlighted that NO₂ and O₃ were the most significant Air Quality Index components influencing DAS28 scores. NO₂ had a lag effect of two months (<i>P</i> &lt; 0.01, effect score = 0.43), whereas O₃ exhibited a lag effect of three months (<i>P</i> &lt; 0.05, effect score = 0.31), both correlating with increased RA disease activity. The study used a Vector Error Correction Model and cointegration analysis to examine short- and long-term associations between predicted and actual DAS28 scores was adjusted over the following year using air quality index, indicating that strong long-term cointegration with the error correction term was negative and significant (−0.54, <i>P</i> &lt; 0.001).</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusion</h3>\u0000 \u0000 <p>These findings emphasize the importance of air quality management in mitigating the impact of environmental factors on RA, suggesting that exposure to elevated levels of NO₂ and O₃ beyond regulatory standards could exacerbate RA symptoms. This study provides a foundation for future public health interventions aimed at improving disease prognosis in patients with RA by addressing environmental factors, such as air pollution.</p>\u0000 </section>\u0000 </div>","PeriodicalId":8406,"journal":{"name":"Arthritis Care & Research","volume":"77 11","pages":"1340-1349"},"PeriodicalIF":3.3,"publicationDate":"2025-06-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144282241","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Pain sensitivity and chronic pain as a link between analgesic use and cardiovascular/gastrointestinal risk: comment on the article by Kaur et al.","authors":"Ryuichi Minoda Sada","doi":"10.1002/acr.25577","DOIUrl":"10.1002/acr.25577","url":null,"abstract":"","PeriodicalId":8406,"journal":{"name":"Arthritis Care & Research","volume":" ","pages":""},"PeriodicalIF":3.7,"publicationDate":"2025-06-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144198169","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Agreement of Administrative Pharmacy Dispensing With Self-Reported Use of Oral Prednisone in US Veterans With Rheumatoid Arthritis","authors":"Beth I. Wallace,&nbsp;Bryant R. England,&nbsp;Joshua F. Baker,&nbsp;Michael D. George,&nbsp;Brian C. Sauer,&nbsp;Jorge Rojas,&nbsp;Punyasha Roul,&nbsp;Katherine D. Wysham,&nbsp;Hannah Brubeck,&nbsp;Isaac Smith,&nbsp;Liron Caplan,&nbsp;Paul A. Monach,&nbsp;Gail S. Kerr,&nbsp;Gary Kunkel,&nbsp;Tawnie Braaten,&nbsp;Ted R. Mikuls,&nbsp;Grant W. Cannon","doi":"10.1002/acr.25580","DOIUrl":"10.1002/acr.25580","url":null,"abstract":"<div>\u0000 \u0000 <section>\u0000 \u0000 <h3> Objective</h3>\u0000 \u0000 <p>Administrative claims are used to evaluate oral glucocorticoid use in rheumatoid arthritis (RA), despite limited evidence to support accuracy. We aimed to evaluate the performance of claims-based algorithms for glucocorticoid use compared to self-report in an RA population.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>Participants with RA enrolled at seven Veterans Affairs Rheumatoid Arthritis (VARA) Registry sites were asked six questions as part of clinical care assessing current prednisone use and dose, recent use, “stockpiling,” and receiving prednisone outside the Department of Veterans Affairs (VA). Algorithms using VA prescription claims operationalized current use (active prescription on date of self-report assessment), current dose (that prescription's mean dose), and recent use (active course overlapping the prior 30 or 90 days). We assessed performance characteristics and agreement, benchmarked on self-report.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>Of 284 participants, 13% reported current prednisone use and 20% reported 90-day use. Sensitivity, specificity, positive predictive value, and negative predictive value were 0.70, 0.98, 0.84, and 0.96, respectively, for current use and 0.71, 0.92, 0.72, and 0.92, respectively, for 90-day use. Cohen's κ was 0.68 for current use and 0.63 for 90-day use. Among participants reporting ≤5 mg/day, agreement for dose was high (weighted κ 0.67). One in four participants reported a stockpile, and one in four reported receiving prednisone from a non-VA provider.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusion</h3>\u0000 \u0000 <p>Algorithms derived from VA claims detecting prednisone prescriptions have high validity compared to patient self-report. The modest sensitivity of these algorithms may reflect stockpiling and non-VA prescriptions. These findings form a basis for contextualizing real-world studies of glucocorticoid use in RA and improve clinical estimation of glucocorticoid use not captured in claims.</p>\u0000 </section>\u0000 </div>","PeriodicalId":8406,"journal":{"name":"Arthritis Care & Research","volume":"77 11","pages":"1350-1358"},"PeriodicalIF":3.3,"publicationDate":"2025-06-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12233313/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144198158","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}